The PI3K – mTOR Pathway
How and why we target the PI3K and mTOR pathway in cancer
The PI3K/mTOR pathway has been implicated in breast, prostate, endometrial, ovarian and hematological cancers, among others.
We are currently developing our lead drug candidate, gedatolisib, in metastatic breast cancer.
How and why we target the PI3K and mTOR pathway in cancer
Internal development of a pan-PI3K/mTOR inhibitor
We are using our CELsignia platform to expand new indications for already approved targeted therapies.